

**LIST OF REFERENCES CITED BY APPLICANT**  
(Use several sheets if necessary)

<b>Application Number</b>	10/657,363
<b>Filing Date</b>	September 8, 2003
<b>First Named Inventor</b>	James F. Young
<b>Art Unit</b>	1648
<b>Examiner Name</b>	Hill, Myron G.
<b>Attorney Docket No.</b>	10271-159-999

**U.S. PATENT DOCUMENTS**

*Examiner Initials	Cite No.	Document Number – Kind Code	Publication Date mm/dd/yyyy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

**FOREIGN PATENT DOCUMENTS**

*Examiner Initials	Cite No.	Foreign Patent Document Country Code, Number, Kind Code (if known)	Publication Date mm/dd/yyyy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T

**NON PATENT LITERATURE DOCUMENTS**

*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	C02	Blake <i>et al.</i> , "Automated Kinetic Exclusion Assays to Quantify Protein Binding Interactions in Homogeneous Solution," <i>Analytical Biochemistry</i> 272: 123-134 (1999).	
	C03	Chamat <i>et al.</i> , "Human Monoclonal Antibodies Isolated from Spontaneous Epstein-Barr Virus—Transformed Tumors of Hu-SPL-SCID Mice and Specific for Fusion Protein Display broad Neutralizing Activity Toward respiratory Syncytial Virus," <i>The Journal of Infectious Diseases</i> , 180:268-77 (1999).	
	C04	Heard <i>et al.</i> , "Two Neutralizing Human Anti-RSV Antibodies: Cloning, Expression, and Characterization," <i>Molecular Medicine</i> 5:35-45 (1999).	
	C05	Wu <i>et al.</i> , "Ultra-potent Antibodies Against Respiratory Syncytial Virus: Effects of Binding Kinetics and Binding Valence on Viral Neutralization," <i>J. Mol. Biol.</i> 350:126-144 (2005).	
	C06	Wu <i>et al.</i> , "Development of Motavizumab, an Ultra-potent Antibody for the Prevention of Respiratory Syncytial Virus Infection in the Upper and Lower Respiratory Tract," <i>J. Mol. Biol.</i> 368:652-665 (2007).	
	C07	MedImmune, Inc. Annual Report (2001).	

LAI-2955781v1

**EXAMINER  
SIGNATURE**

**DATE CONSIDERED**

\*EXAMINER. Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.